Selva Therapeutics, Inc.

Selva has a clinical-stage drug candidate to treat Covid-19.

  • Stage Product In Development
  • Industry Biotechnology
  • Location San Diego, CA, USA
  • Currency USD
  • Founded February 2017
  • Employees 2
  • Incorporation Type C-corp
  • Website selvarx.com

Company Summary

Selva is developing S-001, a novel protease inhibitor as a treatment for Covid-19. S-001 is safe in a range of animals and efficacious in in vitro studies. Selva has GMP material on hand to support initial clinical development. Selva has FDA pre-IND feedback, plans to open an IND in July and complete clinical development in 12 months.

Team

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free